SMi present the 3rd Annual Cancer Vaccines Conference taking place in Central London on Monday 15th and Tuesday 16th September 2014.
This year's event will focus on the pre-clinical entities that are crucial when moving forward in clinical trials. This will include, assessing antigen discovery and genome sequencing in addition to evaluating biomarkers and chimeric antigen receptors.
There is a growing demand for combination therapies and assessing clinical trial design, especially with failures in the clinic increasing, the question to be asked is how can we learn from this and move forward to ensure phase III developments and regulatory approval?
The agenda will focus on in vivo targeting of antigens to dendritic cells for therapeutic anti-cancer vaccines, reviewing preventive vaccine novel adjuvants programmes aswell as evaluating patient stratification.
Furthermore, it will enable a broad range of academics, small biotechs and large pharmaceutical companies to review analytical methods to enable reliability upon standardisation of assays. In addition to assessing the modulation of the tumour microenvironment within early stages of their research and development.
